Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases

肺生物学和肺部疾病中的干细胞、细胞疗法和生物工程

基本信息

批准号：
10753310
负责人：
Amy Leanne Ryan
金额：
$ 3.5万
依托单位：
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-07-15 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10753310
关键词：
3-Dimensional Address American Animal Model Area Award Basic Science Biology Biomedical Engineering Blinded Career Mobility Cell Therapy Cells Chest Clinic Clinical Clinical Research Communication Communities Critical Illness Cystic Fibrosis Data Development Disease European Event Faculty Fostering Foundations Funding Funding Agency Funding Opportunities Future Goals Grant Growth Guidelines Hybrids Immune response Injury International Journals Lung Lung diseases Mentors Molecular Motivation National Heart, Lung, and Blood Institute Natural regeneration Oral Participant Pathologic Persons Physiology Postdoctoral Fellow Pre-Clinical Model Publishing Pulmonary Fibrosis Recommendation Regulation Research Research Personnel Research Support Respiratory Disease Role Science Series Societies Stem Cell Research Students Therapeutic Time Tissue Engineering Training Translating Translational Research Transplantation Travel Underrepresented Minority Underrepresented Populations United States National Aeronautics and Space Administration United States National Institutes of Health Universities Vermont Woman Women&apos s Group airway regeneration career development combat design graduate student immunoregulation induced pluripotent stem cell innovation insight lung development lung injury lung regeneration meetings phrases postdoctoral investigator posters programs repaired respiratory scaffold scientific organization skill acquisition stem cells symposium technology/technique translational study

项目摘要

Project Summary Repair and regeneration of a diseased lung with stem cells or bioengineered tissues are exciting potential therapeutic approaches for a variety of lung diseases and critical illnesses. Over the past decade, increasing evidence in preclinical models suggests that cells which are not normally resident in the lung can be utilized to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those utilizing stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in understanding the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise and differentiate during lung development and in normal and pathologic repair and remodeling after lung injury. We have held nine previous biennial conferences at the University of Vermont from 2005 through 2021. The previous conferences, and the planned 2023 conference, have filled an important niche in the rapidly moving fields of stem cells, cell therapies, lung biology, and bioengineering. Conducted in the style of the Gordon Conferences, there are no other comparable meetings that allow the depth and breadth of discussion, deliberation, and connection that occurs. Importantly, in addition to participation by leading figures in lung biology and disease, we have regularly attracted prominent (non-lung) stem cell experts to give featured plenary presentations, bringing innovation into the field. This is an important feature of the program and is a continuing mark of the stature and importance of the conference. These conferences have been highly successful and have resulted in a series of guidelines for basic, translational, and clinical research to be utilized by both investigators and funding agencies. As studies on stem cell and cell therapies for lung diseases continues to move at a rapid pace and the field explores how to best translate these approaches, we propose to again convene the relevant investigators as well as representatives from the NHLBI, FDA, and leading non-profit respiratory disease foundations to discuss current issues. As always, junior investigators, trainees, and investigators from underrepresented groups will be prioritized for inclusion in conference organization, oral presentations, chairing activities, discussions, and poster sessions. Trainees will be able to compete for an increased number of travel awards based on blinded review of submitted abstracts. The conference is planned as an in-person event with a hybrid online option to increase participation of underrepresented minorities and overseas students in July 2023 at the University of Vermont. We anticipate that this conference will continue to foster extensive discussion and debate and will significantly guide directions in basic, translational, and clinical research of stem cells, cell therapies, and bioengineering approaches for lung diseases.

项目概要用干细胞或生物工程组织修复和再生患病的肺具有令人兴奋的潜力多种肺部疾病和危重疾病的治疗方法。过去十年来，不断增加临床前模型中的证据表明，通常不存在于肺部的细胞可用于调节受伤后的免疫反应，但在转化这些有希望的发现方面存在挑战到诊所。与此同时，生物工程研究激增，调查人工和生物技术的使用无细胞肺基质作为三维肺或气道再生的支架，最近进行了一些尝试大型动物模型移植。这些研究与利用干细胞的研究相结合，诱导多能干细胞衍生物和/或细胞疗法是一项有前途且快速发展的研究区域。这些研究进一步平行于对分子和分子的理解的显着增加。内源性肺干细胞和/或祖细胞在肺过程中产生和分化的细胞事件发育以及肺损伤后的正常和病理修复和重塑。此前我们已举办过九届 2005 年至 2021 年在佛蒙特大学每两年召开一次会议。之前的会议以及计划于 2023 年举行的会议，在快速发展的干细胞、细胞疗法、肺生物学和生物工程。以戈登会议的风格进行，没有其他会议类似的会议可以进行深度和广度的讨论、审议和联系。重要的是，除了肺生物学和疾病领域的领军人物参与之外，我们还定期吸引著名（非肺）干细胞专家将在全体会议上发表特色演讲，将创新带入该领域。这是该计划的一个重要特征，也是该计划的地位和重要性的持续标志。会议。这些会议非常成功，并产生了一系列关于基本、研究人员和资助机构都可以利用转化和临床研究。作为对干的研究肺部疾病的细胞和细胞疗法继续快速发展，该领域正在探索如何最好地为了转化这些方法，我们建议再次召集相关调查人员和代表来自 NHLBI、FDA 和领先的非营利性呼吸系统疾病基金会的专家来讨论当前的问题。作为始终，初级调查员、实习生和来自代表性不足群体的调查员将被优先考虑参与会议组织、口头报告、主持活动、讨论和海报会议。学员将能够根据所提交的资料进行盲审，争夺更多的旅行奖励摘要。该会议计划作为现场活动，并结合在线混合选项以增加参与度 2023 年 7 月，佛蒙特大学的代表性不足的少数族裔和海外学生。我们预计本次会议将继续引发广泛讨论和辩论，对方向具有重要指导意义干细胞、细胞疗法和肺生物工程方法的基础、转化和临床研究疾病。